Nanopatch technology is being commercialised by Vaxxas Pty Ltd, which has scaled the Nanopatch from use in small models to prototypes for human use. Vaxxas CEO Mr David Hoey said the first human vaccination studies are scheduled for this year. "Key attributes of the Nanopatch, including its...